Last week, John Chu, an analyst at Desjardins, reiterated his “HOLD” recommendation on Canopy Growth in anticipation of the second quarter’s financial statements, which should be released on November 14 before the markets open.
Analyst has revised the sales forecast downward and will adjust its targets following the release of the financial statements
According to John Chu, the potential catalysts are
- US federal legalization
- Successful clinical trials
- Increased exports to Europe
- Finding a successor Bruce Linton
Its target of $46 is based on 26X FY2023 EBITDA
This article is written and published by The Cannabis Stock
Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best publication on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result.